Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX -9.09% Days Sales Outstanding is 37.53 as of Jun. 2026, which is 40% below its 10-year median of 62.68. The stock has 2 warning signs investors should review. Among 809 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 87.64% on this metric.
The historical rank and industry rank for Lumos Diagnostics Holdings's Days Sales Outstanding or its related term are showing as below:
ASX:LDX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.82 Med: 62.68 Max: 130.13
Current: 36.26
During the past 5 years, Lumos Diagnostics Holdings's highest Days Sales Outstanding was 130.13. The lowest was 24.82. And the median was 62.68.
ASX:LDX's Days Sales Outstanding is ranked better than 87.64% of 809
companies
in the Medical Devices & Instruments industry
Industry Median: 64.94
vs ASX:LDX: 36.26
Lumos Diagnostics Holdings's Days Sales Outstanding
declined
from Jun. 2025 (51.20) to Jun. 2026 (37.53).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings Days Sales Outstanding Chart
ASX:LDX vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Days Sales Outstanding falls into.
Lumos Diagnostics Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a Days Sales Outstanding of 37.53 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lumos Diagnostics Holdings and its competitors. This is 40% below median its historical median of 62.68. Over the past decade, Lumos Diagnostics Holdings' Days Sales Outstanding has ranged from 24.82 to 130.13. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #100 out of 809 companies in the Medical Devices & Instruments industry, placing it in the top 12.4%.
Is Lumos Diagnostics Holdings' Days Sales Outstanding too high?
Lumos Diagnostics Holdings' current Days Sales Outstanding of 37.53 is 40% below median its 10-year median of 62.68. Over the past 10 years, this metric has ranged from a low of 24.82 to a high of 130.13. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. Lumos Diagnostics Holdings' value of 37.53 is 42.2% below this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #100 out of 809 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Lumos Diagnostics Holdings' Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #100 out of 809 companies for Days Sales Outstanding. This places Lumos Diagnostics Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 64.94. Lumos Diagnostics Holdings' value of 37.53 is 42.2% below this benchmark. Historically, Lumos Diagnostics Holdings' own Days Sales Outstanding has ranged from 24.82 to 130.13 over the past decade. While the company's 10-year median is 62.68 vs. the industry median of 64.94, Lumos Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Days Sales Outstanding of 37.53 is 42.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Days Sales Outstanding is 37.53, which is 40% below median its own 10-year median of 62.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.10 — trading 233.3% above its estimated fair value. The current Days Sales Outstanding is 37.53, which is 40% below median its 10-year median of 62.68 and 42.2% below the Medical Devices & Instruments industry median of 64.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Days Sales Outstanding is 37.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
